# EDGAR Filing Document

**Accession Number:** 0001758009
**File Stem:** 0001213900-23-001786
**Filing Date:** 2023-1
**Character Count:** 20204
**Document Hash:** a61d3760a288c8961a58c2690a2aeca7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-001786.hdr.sgml**: 20230110

**ACCESSION NUMBER**: 0001213900-23-001786

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230104

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230110

**DATE AS OF CHANGE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quantum Computing Inc.
- **CENTRAL INDEX KEY:** 0001758009
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-PREPACKAGED SOFTWARE [7372]
- **IRS NUMBER:** 824533053
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40615
- **FILM NUMBER:** 23519332

**BUSINESS ADDRESS:**
- **STREET 1:** 215 DEPOT COURT SE, #215
- **CITY:** LEESBURG
- **STATE:** VA
- **ZIP:** 20175
- **BUSINESS PHONE:** 703-436-2161

**MAIL ADDRESS:**
- **STREET 1:** 215 DEPOT COURT SE, #215
- **CITY:** LEESBURG
- **STATE:** VA
- **ZIP:** 20175

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 4, 2023**

**<u>QUANTUM COMPUTING INC.</u>**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40615** | **82-4533053** |
| **(State or other jurisdiction<br> of incorporation)** | **(Commission File Number)** | **(IRS Employer<br> Identification No.)** |

---

**215 Depot Court, SE, Suite 215**

**<u>Leesburg, VA 20175</u>**

**(Address of principal executive offices, including zip code)**

**<u>(703) 436-2161</u>**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common shares (par value $0.0001 per share) | QUBT | NASDAQ |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

<u>Director Appointment</u>

On January 4, 2023, the Board of Directors (the "Board") of Quantum Computing Inc. (the "Company") appointed Dr. Carl Weimer, PhD as a member of the Board (the "Appointment"). Dr. Weimer will also serve as a member of the Compensation committee and the Governance & Nominating committee of the Board (the "Committees").

*Carl Weimer, 61, Director*

Dr. Weimer combines over 25 years of experience in the aerospace industry. Previously, he had been involved in two companies in the aerospace industry holding positions including Team Leader, Principal Investigator and Chief Technologist. From 1994 through 2000, Dr. Weimer was a Team Leader for Ophir Corporation, an aerospace optics company. From 2000 to 2018, he was a Team Leader for Ball Aerospace & Technologies Corp., a spacecraft company. From 2018 to present, Dr. Weimer has been the Chief Technologist for the Ball Civil Business Unit. In addition, from 2008 to present, Dr. Weimer has been the Principal Investigator for the NASA Earth Science Technology Office. Dr. Weimer received a Bachelor of Science degree from Harvey Mudd College (1984) and a Master of Science (1987) and a PhD (1992) from Colorado State University all in experimental Physics.

The Board believes that Dr. Weimer's experience in advanced technology leadership roles makes him ideally qualified to help lead the Company towards continued growth and success.

*Family Relationships*

 

Dr. Weimer does not have a family relationship with any of the current officers or directors of the Company.

*Related Party Transactions*

 

There are no related party transactions with regard to Dr. Weimer reportable under Item 404(a) of Regulation S-K.

*Compensatory Arrangements*

 

In connection with the Appointment, the Company and Dr. Weimer entered into a director agreement (the "Director Agreement") whereby, as compensation for his services as a member of the Board and the Committees, Dr. Weimer shall receive, on an annual basis (i) a salary of $36,000, payable on a quarterly basis; and (ii) options to purchase One Hundred Thousand (100,000) shares of the Company's common stock.

Item 5.02 of this Current Report on Form 8-K contains only a brief description of the material terms of and does not purport to be a complete description of the rights and obligations of the parties to the Director Agreement, and such description is qualified in its entirety by reference to the full text of the Director Agreement, which is filed hereto as Exhibit 10.1 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits*.*

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 10.1 | [Director Agreement, dated January 6, 2023.](ea171450ex10-1_quantum.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **<u>QUANTUM COMPUTING INC.</u>** | **<u>QUANTUM COMPUTING INC.</u>** |
| Date: January 9, 2023 | By: | */s/ Robert Liscouski* |
|  | Name: | Robert Liscouski |
|  | Title: | President, Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**QUANTUM COMPUTING INC.**

**215 Depot Court SE, Suite 215**

**Leesburg, VA 20175**

Date: January 6, 2023

Dr. Carl Weimer, PhD

4751 Summerlin Place

Longmont, CO 80503-3921

Dear Dr. Weimer,

This is to confirm the terms of your appointment as a Non-Executive Director of **Quantum Computing Inc.** (the "**Company**") and a member of the Compensation and Governance & Nominating committees. This letter is effective as of January 4, 2023, the date you were elected to the Board.

Overall, in terms of time commitment, we expect your attendance at all the Board of Directors (the "**Board**") meetings, meetings of the audit, compensation and nomination committees of the Board (as applicable) and the General Meetings (if requested). In addition, you will be expected to devote appropriate preparation time ahead of each meeting. Board meetings may be held within or outside Virginia as the Company may decide.

By accepting this appointment, you have confirmed that you are able to allocate sufficient time to meet the expectations of this position.

For and in consideration of the services to be performed by you, Company agrees to pay you as follows:

1.1  **<u>Fee</u>** . An annual fee equal to the amount of $36,000.00 (Thirty-Six Thousand U.S. Dollars), payable on a quarterly basis, subject to your continuous service as a member of the Board (the "**Annual Fee** ").

1.2  **<u>Stock Options.</u>** Subject to all approvals required by law, the Company will grant you options to purchase 100,000 shares of common stock each year that you remain in service as a Non-Executive Director, the exercise price to be set at the closing stock price on the date of grant, vesting quarterly over a one year period from the first day of each year.

**<u>Certain Representations</u>.** You represent and agree that you are accepting the shares of common stock being issued to you pursuant to this Agreement for your own account and not with a view to or for sale of distribution thereof. You understand that the securities are restricted securities and you understand the meaning of the term "restricted securities." You further represent that you were not solicited by publication of any advertisement in connection with the receipt of the shares and that you have consulted tax counsel as needed regarding the shares.

1.3 Company agrees to reimburse you for out-of-pocket expenses incurred by you in connection with your service (including out-of-pocket expenses and "Business Class" transportation expenses, provided that such expenses are against original and valid receipts and pre-approved by the Company in writing (the "**Expenses** ").

1.4 Payment of the Expenses, as applicable, shall be made against your itemized invoice following the receipt of the relevant invoice, which invoice shall be submitted to the Company within seven (7) days of the end of each calendar month during the term of this letter of appointment.

1.5 For the avoidance of any doubt, the Annual Fee and the aforementioned Expenses constitute the full and final consideration for your appointment, and you shall not be entitled to any additional consideration, of any form, for your appointment and service.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The
term of your appointment as a Non-Executive Director of the Company shall be for one year or until the next Annual Meeting of Stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. You
will undertake such travelling as may reasonably be necessary for the performance of your duties, including travelling overseas
for Board meetings and site visits if required.

4. You will undertake such duties and powers relating to the Company, and any subsidiaries or associated companies of the Company (the "**Group**") as the Board may from time to time reasonably request. Directors have the same general legal responsibilities to the Company as any other director. The Board as a whole is collectively responsible for promoting the success of the Company by directing and supervising the Company's affairs, *inter alia*, as follows:

● Providing entrepreneurial leadership of the Group within a framework of prudent and effective controls which enable risk to be assessed and managed; and · Setting the Group's strategic aims, ensures that the necessary financial and human resources are in place for the Group to meet its objectives and reviews management performance; and

● Setting the Group's values and standards and ensures that its obligations to its shareholders and others are understood and met.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.** **Confidential Information** 

You undertake to the Company that you shall maintain in strict confidentiality all trade, business, technical or other information regarding the Company, the Group, its affiliated entities and their business affairs including, without limitation, all marketing, sales, technical and business know-how, intellectual property, trade secrets, identity and requirements of customers and prospective customers, the Company's methods of doing business and any and all other information relating to the operation of the Company (collectively, the "**Confidential Information**"). You shall at no time disclose any Confidential Information to any person, firm, or entity, for any purpose unless such disclosure is required in order to fulfil your responsibilities as director. You further undertake that you shall not use such Confidential Information for personal gain.

"**Confidential Information**" shall not include information that (i) is or becomes part of the public domain other than as a result of disclosure by you, (ii) becomes available to you on a non-confidential basis from a source other than the Company, provided that the source is not bound with respect to that information by a confidentiality agreement with the Group or is otherwise prohibited from transmitting that information by a contractual legal or fiduciary obligation, or (iii) can be proven by you to have been in your possession prior to disclosure of the information by the Company. In the event that you are requested or required (by oral questions, interrogatories, requests for information or documents, subpoena, civil investigative demand or other process) to disclose any Confidential Information, it is agreed that you, to the extent practicable under the circumstances, will provide the Company with prompt notice of any such request or requirement so that the Company may seek an appropriate protective order or waive compliance with this paragraph 6. If a protective order or the receipt of a waiver hereunder has not been obtained, you may disclose only that portion of the Confidential Information which you are legally compelled to disclose.

**<u>Blackout Period</u>.** You understand that we have a policy pursuant to which no officer, director or key executive may not engage in transactions in our stock during the period commencing two weeks prior to the end of a fiscal quarter and ending the day after the financial information for the quarter and year have been publicly released. As a member of the audit committee, if you have information concerning our financial results at any time, you may not engage in transactions in our securities until the information is publicly disclosed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.** **Term and Termination** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 Subject
to paragraph 6.1 hereunder, this appointment shall terminate immediately and without claim for compensation on the occurrence of any
of the following events:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.1 if you resign as a director of the Company for any reason; and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.2 if this appointment is cancelled by the holder or the holders of the shares by which you were appointed; and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.3 if you were appointed by other directors in order to temporary fill vacancy on the Board and said appointment is cancelled by the Board; and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.4 if you are removed or not re-appointed as a director of the Company at a General Meeting of the Company in accordance with the requirements of Section 141 of the DGCL and/or any other applicable law or regulation (the "**Law**") and/or the Company's Articles of Incorporation; and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.5 if you have been declared bankrupt or made an arrangement or composition with or for the benefit of your creditors; and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.6 if you have been disqualified from acting as a director (including, but not limited to, an event in which you are declared insane or become of unsound mind or become physically incapable of performing your functions as director for a period of at least 60 days); and/or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.7 with
your death and if you are a corporation or either entity, with your liquidation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.8 if
an order of a court having jurisdiction over the Company requires you to resign.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 Any
termination of this letter of appointment shall be without payment of damages or compensation (except that you shall be entitled to any
accrued Fees or Expenses properly incurred under the terms of this letter of appointment prior to the date of such termination).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 On
termination of this appointment, you shall return all property belonging to a Group company, together with all documents, papers, disks
and information, howsoever stored, relating to a Group company and used by you in connection with this position with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Subject
to the proper performance of your obligations to the Company under this letter of appointment and any applicable law, the Company agrees
that you will be free to accept other appointments and directorships provided that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 They
do not in any way conflict with the interests of the Company or any member of the Group; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 They
do not restrict you from devoting the necessary time and attention properly to services to be performed under this letter of appointment;
and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 In
the event that you become aware of any potential conflicts of interest, these must be disclosed to the Chairman and/or the Chief Executive
Officer (the "**CEO**") of the Company as soon as they become apparent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 The
Company acknowledges that you are currently on the Board of Directors of the following companies: None

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. The
Company will put directors' and officers' liability insurance in place and will use commercial reasonable effort to maintain
such coverage for the full term of your appointment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. The
performance of individual directors and the Board and its committees is evaluated annually. If, in the interim, there are
any matters which cause you concern about your position, you should discuss them with the Chairman and/or the CEO as soon as is appropriate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. In
addition to any right pursuant to applicable law, occasions may arise when you consider that you need professional advice
in the furtherance of your duties as a director. Circumstances may occur when it will be appropriate for you to seek such
advice from independent advisors at the Company's expense, to the extent provided under applicable law and subject to the prior
written approval of a majority of the independent directors of the Company and the CEO, such consent shall not be unreasonably withheld.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. This letter refers to your appointment as a director of the Company and your membership of the audit, nomination and the remuneration committees of the board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. You shall ensure that you comply at all times with the Company's inside trading policies as in effect from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. You shall discharge your general duties as a director pursuant to the Company's Articles of Association of the Company and applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. This letter of appointment shall be governed by and construed in accordance with the law of the State of Delaware.

Please sign the attached copy of this letter and return it to the Company to signify your acceptance of the terms set out above.

Sincerely yours,

---

| | | |
|:---|:---|:---|
| QUANTUM COMPUTING INC. | QUANTUM COMPUTING INC. | QUANTUM COMPUTING INC. |
| By: |  |  |
|  | Robert Liscouski | Robert Liscouski |
|  | Chief Executive Officer | Chief Executive Officer |
| By: |  |  |
|  | Dr. Carl Weimer | Dr. Carl Weimer |
|  | Address: | 4751 Summerlin Place <br> Longmont, CO 80503-3921 |

---